QCi and INmune Bio partner to study XPro in Alzheimer's

INmune Bio and QCi have agreed to collaborate using quantum computing, AI, and data analytics to explore new indications for XPro, an investigational treatment for Alzheimer's disease and other medical conditions. Both companies will analyse clinical and biomedical datasets to identify conditions that share the biological mechanisms targeted by XPro. Researchers will combine INmune Bio’s findings from pre-clinical studies and clinical trials with QCi’s Dirac-3S quantum optimisation machine. Credit: Gorodenkoff / Shutterstock.com. INmune Bio and Quantum Computing, known as QCi, have agreed to collaborate using quantum computing, AI, and data analytics to explore new indications for XPro (XPro1595), an investigational…

Source: Pharmaceutical Technology